bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate Read more about bluebird bio Reports Rapid Transfusion Independence in Beta-Thalassemia Major Patients Treated with its LentiGlobin Product Candidate
bluebird bio to Host a Conference Call to Discuss Initial Results from the HGB-205 Study in Beta-Thalassemia Major Subjects Read more about bluebird bio to Host a Conference Call to Discuss Initial Results from the HGB-205 Study in Beta-Thalassemia Major Subjects
bluebird bio to present initial clinical data from its HGB-205 Study in beta-thalassemia major patients at the 19th European Hematology Association Congress Read more about bluebird bio to present initial clinical data from its HGB-205 Study in beta-thalassemia major patients at the 19th European Hematology Association Congress
bluebird bio Reports Fiscal First Quarter 2014 Financial Results Read more about bluebird bio Reports Fiscal First Quarter 2014 Financial Results
bluebird bio to Present at Three Upcoming Health Care Conferences Read more about bluebird bio to Present at Three Upcoming Health Care Conferences
bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia Read more about bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia
bluebird bio Reports Fiscal Year End 2013 Financial Results Read more about bluebird bio Reports Fiscal Year End 2013 Financial Results
bluebird bio to Present at the Cowen and Company Health Care Conference Read more about bluebird bio to Present at the Cowen and Company Health Care Conference
bluebird bio to Present at the Leerink Global Healthcare Conference Read more about bluebird bio to Present at the Leerink Global Healthcare Conference
bluebird bio Appoints Dr James Mandell to its Board of Directors Read more about bluebird bio Appoints Dr James Mandell to its Board of Directors